NUNaomi Uemura

Naomi Uemura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naomi Uemura has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 December 2011
      • Vol. 62  (6) , 627-35

    Evidence-based therapy according to the guideline for gastric ulcers is cost-effective in Japan.

    by Kiyomi Taniyama, T Shimbo, H Iwase, S Tanaka, N Watanabe, N Uemura

    Helicobacter pylori (H. pylori) infection is a major cause of gastric ulcers (GU) and eradication of the infection controls the ulcer with no requirement for maintenance therapy. In Japan, an evidence-based guideline (GL) was first published in 2003 (1(st) version) and then again in 2007 (2(nd) version) with a minor revision under support of the Japanese Ministry of Health, Labor and Welfare (GUGLJ). Adherence to its standards is high, estimated at 80%. GU patients aged 18 or older with active ulcers at the time of diagnosis by an endoscopic examination at National Hospital Organization (NHO) hospitals of Japan were enrolled between September 2004 and April 2005. Subjective and endoscopic outcome, medical treatments and medical costs during the following nine months were analyzed, retrospectively. As a result, 935 patients and 270 doctors in charge from 62 NHO hospitals were analyzed. Among H. pylori-positive GU patients, the endoscopic recurrence rate of 24 patients with failure of eradication was 29.2%, which was significantly higher than 8.8% of 194 patients with successful eradication. Successful eradication of H. pylori resulted in significantly lower endoscopic recurrence rates for GU patients either with or without administration of non-steroidal anti-inflammatory drugs (NSAID). GUGLJ adherence scores were significantly related to the specialty or knowledge on the GUGLJ of doctors in charge, and the total medical cost consumed. These results suggest that the therapy of GU along with an evidence-based GL is essential to implement cost-effective treatment and the GI experts or the doctors that understand the GUGLJ very well should perform it.


  • Top Cited Papers

    Helicobacter pyloriInfection and the Development of Gastric Cancer

    by Naomi Uemura, Shiro Okamoto, Soichiro Yamamoto, Nobutoshi Matsumura, Shuji Yamaguchi, Michio Yamakido, Kiyomi Taniyama, Naomi Sasaki, Ronald J. Schlemper

    Although many studies have found an association between Helicobacter pylori infection and the development of gastric cancer, many aspects of this relation remain uncertain. We prospectively studied 1526 Japanese patients who had duodenal ulcers, gastric ulcers, gastric hyperplasia, or nonulcer dyspepsia at the time of enrollment; 1246 had H. pylori infection and 280 did not. The mean follow-up was 7.8 years (range, 1.0 to 10.6). Patients underwent endoscopy with biopsy at enrollment and then between one and three years after enrollment. H. pylori infection was assessed by histologic examination, serologic testing, and rapid urease tests and was defined by a positive result on any of these tests. Gastric cancers developed in 36 (2.9 percent) of the infected and none of the uninfected patients. There were 23 intestinal-type and 13 diffuse-type cancers. Among the patients with H. pylori infection, those with severe gastric atrophy, corpus-predominant gastritis, and intestinal metaplasia were at significantly higher risk for gastric cancer. We detected gastric cancers in 21 (4.7 percent) of the 445 patients with nonulcer dyspepsia, 10 (3.4 percent) of the 297 with gastric ulcers, 5 (2.2 percent) of the 229 with gastric hyperplastic polyps, and none of the 275 with duodenal ulcers. Gastric cancer develops in persons infected with H. pylori but not in uninfected persons. Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk. Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.


    • 1 January 2001
      • Vol. 98  (1) , 25-30

    [A case of small cell carcinoma of esophagus successfully treated by chemotherapy with CPT-11 and CDDP].

    by Y Komura, N Uemura, S Okamoto, S Yamamoto, N Matsumura, S Yamaguchi, N Sasaki, K Taniyama

  • Open Access

    Changes in Helicobacter pylori‐induced gastritis in the antrum and corpus during long‐term acid‐suppressive treatment in Japan

    by N. Uemura, S. Okamoto, S. Yamamoto, N. Matsumura, S. Yamaguchi, H. Mashiba, N. Sasaki, K. Taniyama

    Background: Several studies have shown that acid‐suppressive therapy aggravates corpus gastritis in patients with Helicobacter pylori infection, promoting the development of atrophic gastritis. Aim: To study the effects of long‐term use of antisecretory agents on the H. pylori‐positive gastric mucosa in Japan, a country with a high incidence of gastric cancer. Methods: A total of 141 H. pylori‐positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134). Endoscopy was performed before, during, and after treatment. Biopsy specimens were taken from the greater curvature of the antrum and corpus and were examined histologically. Results: The long‐term use of famotidine after 8 weeks of treatment with omeprazole distinctly decreased H. pylori density and neutrophil infiltration in the antrum, but did not change H. pylori density in the corpus. The gastritis score increased in patients who had no, or only mild corpus gastritis before treatment (n=74), and significantly decreased in those who had moderate or severe gastritis before treatment (n=60). In four of the seven patients who received long‐term treatment with omeprazole alone, neutrophil infiltration and H. pylori density decreased not only in the antrum but also in the corpus. There was no increase in intestinal metaplasia or mucosal atrophy as assessed endoscopically during follow‐up. Conclusion: Changes in corpus gastritis in response to acid‐suppressive therapy depend on the severity of gastritis before treatment. Long‐term use of acid‐suppressive therapy apparently does not accelerate the development of atrophy or intestinal metaplasia in Japanese patients.


    • 1 January 1998
      • Vol. 29, 381-93

    Spontaneous regression of malignant lymphoma of the stomach.

    by D Ogawa, N Uemura, N Sasaki, T Mukai, S Yamaguchi, S Okamoto, S Yamamoto, H Mashiba, K Taniyama

    We report a case of complete and spontaneous regression of malignant lymphoma of the stomach. A submucosal tumor with central ulceration was detected on the greater curvature of the stomach in a 63-year-old woman. The tumor was diagnosed histopathologically as a diffuse large B-cell lymphoma (REAL classification). The tumor disappeared 18 days later without chemotherapy. Examination at that stage showed Helicobacter pylori (H. pylori), which was later treated with antibiotics. There was no evidence of recurrence of the malignant lymphoma at the last follow-up conducted at the time of preparation of this report, 13 months after the initial diagnosis. Spontaneous regression of an intermediate and high-grade non-Hodgkin's lymphoma is uncommon. We discuss the possible role of H. pylori in the regression of gastric malignant lymphomas.


  • Autologous bone marrow transplantation for patients with advanced chronic myelogenous leukemia.

    by T Nagamura-Inoue, A Tojo, K Ikebuchi, S Takahashi, H Ogura, E Shindoh, F Nagamura, N Uemura, K Watari, S Irie, et al.

    We report on seven chronic myelogenous leukemia (CML) patients who received autologous bone marrow transplantation (ABMT) using bone marrow (BM) cells while at the chronic phase (CP) under the various treatments. Of the seven patients, four progressed to accelerated phase (AP) in 83-248 weeks after onset and three patients entered blastic crisis (BC) in 84-171 weeks after onset. All patients received high-dose chemoradiotherapy followed by infusion with 11.3 +/- 12.1 x 10(7) (average +/- S.D.) of bone marrow mononuclear cells (BM-MNCs)/kg IFN-alpha was resumed shortly after platelet recovery. Of the four patients in AP, one developed a recurrence of blastoma in 7 weeks, one progressed to second AP in 138 weeks after ABMT and two patients have survived the second CP for 159 and 330 weeks since ABMT, respectively. One of them achieved the complete disappearance of Ph1-positive metaphases for 33 weeks after ABMT. Of patients who received AMBT in BC, three relapsed within 8 weeks and died in 9, 17 and 58 weeks after ABMT, respectively. Hematological recovery was delayed in four patients. Therefore, we retrospectively re-evaluated the number of BM-MNCs collected through 50 procedures from 40 patients with CML-CP. The total MNCs obtained from 30 collections under IFN-alpha treatment was 27.4 +/- 30.9 x 10(8) cells (average +/- S.D.), being significantly lower than that obtained from 20 collections in pre-treatment state or with single chemotherapy other than IFN-alpha treatment (81.8 +/- 68.2 x 10(8) cells) (P < 0.005). The total number of MNCs correlated to white blood cell (WBC) count at BM collection (P < 0.01), which was also lower in the IFN-alpha(+) group than in the IFN-alpha(-) group (7.2 +/- 5.7 and 25.6 +/- 32.3 x 10(9)/l; P < 0.005). Our findings suggested that ABMT with the use of a sufficient number of progenitor cells might be helpful to CML patients in early AP and reach in extended periods of second CP. In addition, we suggest that BM collection is required before the start of IFN-alpha therapy because the total number of BM-MNCs correlated to the WBC count, which might be lower in IFN-alpha treatment.


    • 1 August 1997
      • Vol. 6  (8) , 639-42

    Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer.

    by N Uemura, T Mukai, S Okamoto, S Yamaguchi, H Mashiba, K Taniyama, N Sasaki, K Haruma, K Sumii, G Kajiyama

    Although epidemiological studies strongly suggest an association between gastric cancer and Helicobacter pylori infection, there has been no clinical report indicating that cure of the infection prevents cancer. We conducted a nonrandomized H. pylori eradication trial in patients whose gastric cancer was removed by endoscopic resection (ER). We investigated the effect of treatment on the histopathology of the gastric mucosa, as well as on the incidence of metachronous gastric cancer during the long-term clinical and endoscopic follow-up. One hundred and thirty-two patients with early gastric cancer underwent ER and had H. pylori infection. Sixty-five (group A) were treated with omeprazole and antibiotics to eradicate the infection, and 67 (group B) were not. All patients were followed for 2 years post ER. After eradication treatment in group A, the disappearance of neutrophil infiltration in the antrum and body of the stomach was observed as was a decrease of the severity of intestinal metaplasia. Endoscopy after ER detected no new gastric cancers in these patients. After 3 years of follow-up, 6 (9%) of the 67 patients in group B had a new early-stage, intestinal-type gastric cancer endoscopically diagnosed. The above results suggest that H. pylori eradication may improve neutrophil infiltration and intestinal metaplasia in the gastric mucosa and inhibit the development of new carcinomas. This finding should be confirmed in a randomized, controlled trial.


    • 1 November 1996
      • Vol. 37  (11) , 1271-5

    [Bronchiolitis obliterans organizing pneumonia (BOOP) after allogeneic bone marrow transplantation].

    by M Nakayama, S Takahashi, T Inoue, F Nagamura, M Setoyama, J Ooi, T Takahashi, Y Oshima, K Miyamoto, N Uemura, et al.

    We report a patient who underwent allogeneic bone marrow transplantation for ALL. The patient presented low grade fever, cough and dyspnea at day 3 after after bone marrow transplantation. Imaging studies showed bilateral patchy infiltrates on chest X-ray and chest CT. Though treated by antibiotics, chest auscultation recognized marked bilateral inspiratory crackles. Transbronchial lung biopsy performed on day 34 showed bronchiolitis obliterans and an organizing interstitial pneumonia. The patient was treated with methylprednisolone and follow up computed tomography findings improved.

    • 1 August 1995
      • p. S67-9

    Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin.

    by N Uemura, S Okamoto, T Mukai, S Yamaguchi, M Kaji, K Hrruma, K Sumii, G Kajiyama

    To investigate the effect of eradication of Helicobacter pylori using combination therapy with low-dose omeprazole and clarithromycin on the healing and recurrence of peptide ulcers. We studied 60 patients with active duodenal ulcers and 60 with gastric ulcers who were H. pylori-positive by the rapid urease test and a histological examination of antral biopsy specimens. The eradication method used was a combination of omeprazole (20 mg a day) and clarithromycin (400 mg twice a day). The patients were followed up for 24 months after the end of the treatment. H. pylori infection and the ulcer stage were investigated by endoscopy every 6 months. We assessed the relationship between H. pylori infection, ulcer healing to a white scar and ulcer recurrence after combination therapy. H. pylori was eradicated in 23 out of 120 patients (22%), with suppression in 101 out of 120 patients (84%). The rate of ulcer healing to a white scar 6 months after treatment was significantly higher and the ulcer recurrence rate within 2 years after treatment was significantly lower in patients with H. pylori suppression or eradication than in those continuously positive for the organism. These results suggest that not only the eradication but also the suppression of H. pylori may improve ulcer healing and reduce the rate of relapse.